The pentagon and the broad bean


Thursday, 11 October, 2018


The pentagon and the broad bean

Electron microscopes and computerised image analysis has allowed researchers to uncover the correct structure of a protein essential in the immune system, IgM, and a much smaller protein that is bound inside, AIM.

The discovery by University of Tokyo researchers is expected to create future possibilities to develop more effective medicines for a range of illnesses from cancer to neurological diseases.

Researchers verified the structure of natural immunoglobulin M (IgM) protein, an important part of the immune system, using mouse and human versions of the protein. IgM is now understood to be shaped like an incomplete hexagon, or a pentagon with a wedge-shaped gap.

"We'll have to revise the textbooks," said Professor Toru Miyazaki, the leader of the laboratory where the IgM structure was identified at the Graduate School of Medicine.

IgM is the first immune system protein that develops in the human fetus and remains the first responder to pathogens throughout life. The structure of IgM was first identified in 1969 as a "five-pointed, star-shaped table" and updated in 2009 to be a five-sided dome or "mushroom cap".

"The original IgM model was made by looking at a few individual molecules by hand with what today we think is a low-resolution microscope. Now we have clearer pictures and the computer can examine thousands of individual IgM molecules," said Miyazaki.

The 2018 discovery of the incomplete hexagon was actually a secondary interest for Miyazaki, originally a medical doctor who has built his research career studying a different protein called apoptosis inhibitor of macrophage (AIM).

Since identifying the correct shape of IgM, researchers now understand that inactive AIM is nestled inside the gap of the IgM incomplete hexagon. The structural connection between IgM and AIM means that drugs with the ability to regulate the release of AIM could be used to create AIM-based disease therapies.

Miyazaki identified AIM in 1999 while working at the Basel Institute for Immunology Institute in Switzerland. Its small size means AIM is easily eliminated from the body by the kidneys and excreted in urine, so staying bound within the larger IgM protects AIM from being removed before it is needed.

AIM is a common molecule in the bloodstream, but it is only active when the body develops a disease. AIM is known to be important for preventing obesity, fatty liver disease, hepatocellular carcinoma (liver cancer), multiple sclerosis (MS), fungus-induced peritonitis (inflammation of the abdominal wall membrane) and acute kidney injury.

The incomplete hexagon structure is still only a 2D understanding of IgM structure. Miyazaki and his team continue to do additional analysis and hope to report the 3D structure of IgM soon.

Image caption: IgM is the larger, incomplete hexagon shape and AIM is the smaller broad bean shape inside the wedge-shape gap. In the right-side image, AIM is more easily recognised as the bright white, broad-bean-shaped spot. Image by Hiramoto et al., originally published in Science Advances, CC-BY

Related News

Health researchers recognised in 2018 Research Action Awards

Three Australian researchers whose work has had a significant impact on healthcare policy and...

Potential treatment for 'chemobrain' discovered

Scientists have previously believed that chemotherapy was the only cause of chemobrain — a...

New 'immune brake' targeted for tumour control

Researchers have shed light on how some cancers are able to escape our immune system, in a...


  • All content Copyright © 2018 Westwick-Farrow Pty Ltd